NON RARE IN EUROPE: Chronic proteinuria with focal and segmental hyalinosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Dec 1987

Parathar: FDA approved

Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

Parathar

Rhone-Poulenc Rorer Pharmaceuticals, Inc.

OpenContact for details

View all support programs on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for NON RARE IN EUROPE: Chronic proteinuria with focal and segmental hyalinosis.
Search all trials →
Search clinical trials for NON RARE IN EUROPE: Chronic proteinuria with focal and segmental hyalinosis

Recent News & Research

No recent news articles indexed yet for NON RARE IN EUROPE: Chronic proteinuria with focal and segmental hyalinosis.
Search PubMed for NON RARE IN EUROPE: Chronic proteinuria with focal and segmental hyalinosis

Browse all NON RARE IN EUROPE: Chronic proteinuria with focal and segmental hyalinosis news →

Specialist Network

No specialists currently listed for NON RARE IN EUROPE: Chronic proteinuria with focal and segmental hyalinosis.

View all NON RARE IN EUROPE: Chronic proteinuria with focal and segmental hyalinosis specialists →

Quick Actions